Income Insurance Ltd Invests $2.65 Million in Eli Lilly and Company $LLY

Income Insurance Ltd acquired a new position in Eli Lilly and Company (NYSE:LLY) in the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 2,467 shares of the company’s stock, valued at approximately $2,651,000. Eli Lilly and Company comprises 1.7% of Income Insurance Ltd’s holdings, making the stock its 12th biggest holding.

A number of other hedge funds have also recently made changes to their positions in the business. D Orazio & Associates Inc. raised its holdings in shares of Eli Lilly and Company by 15.0% during the 4th quarter. D Orazio & Associates Inc. now owns 2,059 shares of the company’s stock worth $2,213,000 after acquiring an additional 268 shares in the last quarter. Advisor OS LLC raised its holdings in shares of Eli Lilly and Company by 11.0% during the 4th quarter. Advisor OS LLC now owns 6,741 shares of the company’s stock worth $7,245,000 after acquiring an additional 668 shares in the last quarter. Plato Investment Management Ltd raised its holdings in shares of Eli Lilly and Company by 3.6% during the 4th quarter. Plato Investment Management Ltd now owns 18,125 shares of the company’s stock worth $19,574,000 after acquiring an additional 633 shares in the last quarter. Midwest Trust Co raised its holdings in shares of Eli Lilly and Company by 26.8% during the 4th quarter. Midwest Trust Co now owns 63,621 shares of the company’s stock worth $68,372,000 after acquiring an additional 13,464 shares in the last quarter. Finally, Bensler LLC raised its holdings in shares of Eli Lilly and Company by 5.4% during the 4th quarter. Bensler LLC now owns 19,681 shares of the company’s stock worth $21,151,000 after acquiring an additional 1,014 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Barclays raised its price target on Eli Lilly to $1,400 from $1,350 and kept an Overweight rating, reinforcing the market’s view that the company’s long-term growth story remains intact. Barclays Sees Reinforced Long-Term Growth Narrative for Eli Lilly and Company (LLY)
• Positive Sentiment: Investor enthusiasm is also being supported by strong fundamental momentum, including recent commentary that Eli Lilly remains a top momentum stock and continued recognition of its growth profile after a major revenue beat. Why Eli Lilly (LLY) is a Top Momentum Stock for the Long-Term
• Positive Sentiment: Management highlighted strong sales performance, with CFO Lucas Montrace discussing what drove the company’s 56% year-over-year revenue increase, underscoring continued demand for Lilly’s drug portfolio. Eli Lilly CFO Lucas Montrace Explains What Drove 56% Year-over-Year Revenue Beat
• Positive Sentiment: News that Mounjaro has surpassed Merck’s Keytruda as the world’s best-selling drug highlights how quickly Lilly’s obesity and diabetes franchise has become a major earnings driver. Eli Lilly’s Mounjaro surpasses Merck’s Keytruda as best-selling drug
• Neutral Sentiment: Lilly also agreed to acquire Centessa Pharmaceuticals, and the deal is drawing legal scrutiny over price and process; this is a watch item rather than a clear catalyst for the stock. Centessa Pharmaceuticals Investor Alert
• Negative Sentiment: A Reuters report said Lilly halted its obesity awareness campaign in India after regulators questioned whether it could amount to indirect advertising for prescription drugs, adding a small regulatory overhang. Exclusive: Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarity

Eli Lilly and Company Price Performance

LLY opened at $965.85 on Tuesday. The business has a fifty day moving average of $941.13 and a 200 day moving average of $993.05. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The stock has a market cap of $909.58 billion, a P/E ratio of 34.31, a PEG ratio of 1.03 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. During the same quarter in the previous year, the business earned $3.34 EPS. Eli Lilly and Company’s revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company’s payout ratio is presently 24.58%.

Analyst Ratings Changes

Several analysts have recently issued reports on LLY shares. Loop Capital set a $1,200.00 price objective on Eli Lilly and Company in a report on Tuesday, February 10th. Freedom Capital raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 10th. Berenberg Bank raised their price objective on Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a “hold” rating in a research note on Thursday, February 19th. Morgan Stanley reaffirmed an “overweight” rating and issued a $1,344.00 price objective on shares of Eli Lilly and Company in a research note on Friday, May 1st. Finally, Zacks Research lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,218.33.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.